Fujita et al. retrospectively analyzed the limited efficacy of salvage anti-PD-L1 with atezolizumab in 18 non-small lung cancer (NSCLC) patients previously treated with anti-PD-1 (nivolumab, pembrolizumab), noting that none achieved tumor shrinkage [15]. Here, PDCD1 is linked to neoplasm.